Retatrutide: The Triple Agonist GLP-1 Complete Guide (2026)

Retatrutide is Eli Lilly's triple hormone receptor agonist — the first drug to simultaneously activate GLP-1, GIP, and glucagon receptors. Phase 3 data shows 28.7% mean body weight reduction. Here's everything you need to know.

Read more

Support ✨
📞 Call
Hi there! Want to chat via voice? Click the Call button! 😊
🤖
Listening...
Speak naturally with the agent
📞